The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Polyakov A.N.
Blokhin National Cancer Research Center
Patyutko Yu.I.
Blokhin National Medical Research Center of Oncology
Turlak A.S.
Granov Russian Research Center of Radiology and Surgical Technologies
Prognostic factors and preoperative therapy in resectable intrahepatic cholangiocarcinoma
Journal: Pirogov Russian Journal of Surgery. 2025;(1): 5‑13
Views: 799
Downloaded: 44
To cite this article:
Polyakov AN, Patyutko YuI, Granov DA, et al. . Prognostic factors and preoperative therapy in resectable intrahepatic cholangiocarcinoma. Pirogov Russian Journal of Surgery.
2025;(1):5‑13. (In Russ., In Engl.)
https://doi.org/10.17116/hirurgia20250115
To identify prognostic factors and role of preoperative therapy for resectable intrahepatic cholangiocarcinoma (IHCC).
We analyzed the results of surgical and combined treatment of IHCC between 1999 and 2023. Immediate and long-term outcomes were evaluated depending on negative prognostic factors and additional therapy.
The study included 195 patients. Postoperative complications grade ≥III were observed in 35 (17.9%) case. Mortality rate was 3.1% (n=6). Thirty-eight patients (19.5%) underwent treatment before surgery, 109 (55.9%) ones — after surgery. The median overall survival was 31 months, 5-year overall survival — 32.0%. The following factors worsened overall survival: node size ≥8 cm (HR 1.45; 95% CI 0.97—2.17), invasion (HR 1.63; 95% CI 1.07—2.47), multiple lesion (HR 1.51; 95% CI 1.00—2.28). R1 resection worsened disease-free survival (HR 1.88; 95% CI 1.14—3.10). Lymph node metastases decreased overall (HR 1.96; 95% CI 1.27- 3.04) and disease-free survival (HR 2.37; 95% CI 1.63—3.44). Two and more negative factors worsened overall (p=0.0013) and disease-free survival (p=0.0005). Absence of adjuvant therapy worsened overall (HR 2.12; 95% CI 1.41—3.20) and disease-free survival (HR 1.42; 95% CI 0.99—2.04). There was a trend towards higher overall (p=0.088) and progression-free survival (p=0.029) in case of preoperative therapy (n=195). In unfavorable prognosis group, preoperative therapy (n=33) was superior to standard treatment (resection+capecitabine after surgery, n=26). There was a trend towards higher overall survival (p=0.066) and significantly better progression-free survival (17 vs 13 months, p=0.018).
Negative prognostic factors for resectable IHCC are lesion size ≥8 cm, intrahepatic and regional metastases, invasion into neighboring structures, R1 resection. Combination of negative factors worsened prognosis. Adjuvant therapy improved postoperative outcomes. Preoperative therapy may be advisable in case of negative factors and high risk of R1 resection.
Authors:
Polyakov A.N.
Blokhin National Cancer Research Center
Patyutko Yu.I.
Blokhin National Medical Research Center of Oncology
Turlak A.S.
Granov Russian Research Center of Radiology and Surgical Technologies
Received:
09.04.2024
Accepted:
23.04.2024
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.